Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
5000 participants
OBSERVATIONAL
2020-03-30
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Course and Treatment of COVID-19 Inpatients in Hospital
NCT04527497
Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults
NCT04341168
Follow-up of Patients With Previous SARS-CoV-2 Infection: Long-term Damage Assessment
NCT05359159
Epidemiological Multicohort Study of Latent COVID-19 Infections
NCT04695678
Observational Study in COVID-19 Patients Treated With Remdesivir
NCT05239988
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
So far, however, there is little to no experience in treating patients. In addition to epidemiological data, only case descriptions and some Chinese studies mostly from Wuhan based on fewer patients are available. In view of the rapidly spreading pandemic, preprints are increasingly being used. What has been missing so far is a uniform, structured recording of the courses of Covid-19 inpatients handled by many clinics, which goes beyond the epidemiological events in terms of depth of detail. With this documentation of real processes, the basis for a large number of studies and the associated better understanding of the disease process could be created.
The current dynamics make it imperative that the clinics, even those who have not received the most up-to-date scientific knowledge, cannot wait for the results of studies, but rather need concrete help in the treatment of patients. Efficient assistance within the framework of a close exchange between the treatment units is only possible with a multicentre, uniform documentation environment.
The aim of the project is to better understand the Covid-19 inpatient course of the disease and to quickly identify the positive experiences in the treatment in order to update guidelines for the treatment and use of medication.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ClarData
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julia Ferencz, MD
Role: PRINCIPAL_INVESTIGATOR
ClarData
Hans-Rudolf Tinneberg, Prof.
Role: PRINCIPAL_INVESTIGATOR
University of Giessen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
RoMed - Klinikum Bad Aibling
Bad Aibling, , Germany
DONAUISAR Klinikum Deggendorf
Deggendorf, , Germany
DONAUISAR Klinikum Dingolfing
Dingolfing, , Germany
RoMed - Klinikum Prien am Chiemsee
Prien am Chiemsee, , Germany
RoMed - Klinikum Rosenheim
Rosenheim, , Germany
Universitätsklinikum Ulm
Ulm, , Germany
RoMed - Klinikum Wasserburg Am Inn
Wasserburg am Inn, , Germany
Klinikum Altmühlfranken
Weißenburg, , Germany
Timiş County Emergency Clinical Hospital
Timișoara, , Romania
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Stefan Budweiser, Prof.
Role: primary
Adi Kovacevic, Dr.
Role: primary
Heribert Fröschl, Dr.
Role: primary
Stefan Budweiser, Prof.
Role: primary
Stefan Budweiser, Prof.
Role: primary
Thomas Seufferlein, Prof
Role: primary
Stefan Budweiser, Prof.
Role: primary
Marius Ghidau, Dr.
Role: primary
Ovidiu Bedreag, Prof.
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Budweiser S, Bas S, Jorres RA, Engelhardt S, von Delius S, Lenherr K, Deerberg-Wittram J, Bauer A. Patients' treatment limitations as predictive factor for mortality in COVID-19: results from hospitalized patients of a hotspot region for SARS-CoV-2 infections. Respir Res. 2021 Jun 4;22(1):168. doi: 10.1186/s12931-021-01756-2.
Related Links
Access external resources that provide additional context or updates about the study.
This is the website of the study and database
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CovidDB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.